BR0213181A - Combinações de inibidor de cox-2 - Google Patents

Combinações de inibidor de cox-2

Info

Publication number
BR0213181A
BR0213181A BR0213181-1A BR0213181A BR0213181A BR 0213181 A BR0213181 A BR 0213181A BR 0213181 A BR0213181 A BR 0213181A BR 0213181 A BR0213181 A BR 0213181A
Authority
BR
Brazil
Prior art keywords
cox
inhibitor combinations
inhibitor
combinations
mammals
Prior art date
Application number
BR0213181-1A
Other languages
English (en)
Inventor
Alberto Gimona
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0213181A publication Critical patent/BR0213181A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES DE INIBIDOR DE COX-2". A invenção refere-se a uma composição farmacêutica que é provida para o tratamento de condições em mamíferos que são responsáveis pela inibição de COX-2 que compreende em combinação um inibidor de COX-2 e aspirina em baixa dose para o uso simultâneo, seq³encial ou separado.
BR0213181-1A 2001-10-11 2002-10-10 Combinações de inibidor de cox-2 BR0213181A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124459.9A GB0124459D0 (en) 2001-10-11 2001-10-11 Organic compounds
PCT/EP2002/011380 WO2003033001A1 (en) 2001-10-11 2002-10-10 Combinations comprising cox-2 inhibitors and aspirin

Publications (1)

Publication Number Publication Date
BR0213181A true BR0213181A (pt) 2004-08-31

Family

ID=9923664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213181-1A BR0213181A (pt) 2001-10-11 2002-10-10 Combinações de inibidor de cox-2

Country Status (19)

Country Link
US (2) US20040235802A1 (pt)
EP (1) EP1435968A1 (pt)
JP (1) JP2005505606A (pt)
KR (1) KR20040044891A (pt)
CN (1) CN1625405A (pt)
AU (1) AU2006249254A1 (pt)
BR (1) BR0213181A (pt)
CA (1) CA2458981A1 (pt)
CO (1) CO5570661A2 (pt)
GB (1) GB0124459D0 (pt)
HU (1) HUP0401854A2 (pt)
IL (1) IL160620A0 (pt)
MX (1) MXPA04003365A (pt)
NO (1) NO20041432L (pt)
NZ (1) NZ532158A (pt)
PL (1) PL369005A1 (pt)
RU (1) RU2004114560A (pt)
WO (1) WO2003033001A1 (pt)
ZA (1) ZA200401302B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
JP2006501161A (ja) 2002-06-11 2006-01-12 ニトロメッド インク． ニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物ならびに使用方法
CN1914149A (zh) * 2004-01-27 2007-02-14 默克弗罗斯特公司 用于治疗处于血栓形成心血管事件危险中的患者的环氧合酶－2为媒的疾病或状况的组合治疗
WO2007036809A2 (en) * 2005-05-24 2007-04-05 Flamel Technologies S.A. Novel acetylsalicylic acid formulations
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
CN101257800B (zh) * 2005-07-18 2012-07-18 好利用医疗公司 包含法莫替丁和布洛芬的药物
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US10272107B2 (en) * 2017-09-05 2019-04-30 Kenneth O. Russell Method for treating inflammatory brain disorders and traumatic brain injury
US10586872B2 (en) * 2018-07-03 2020-03-10 International Business Machines Corporation Formation of wrap-around-contact to reduce contact resistivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid

Also Published As

Publication number Publication date
US20040235802A1 (en) 2004-11-25
GB0124459D0 (en) 2001-12-05
JP2005505606A (ja) 2005-02-24
WO2003033001A1 (en) 2003-04-24
PL369005A1 (en) 2005-04-18
CO5570661A2 (es) 2005-10-31
CN1625405A (zh) 2005-06-08
IL160620A0 (en) 2004-07-25
EP1435968A1 (en) 2004-07-14
NO20041432L (no) 2004-06-28
AU2006249254A1 (en) 2007-01-04
HUP0401854A2 (hu) 2004-12-28
CA2458981A1 (en) 2003-04-24
NZ532158A (en) 2006-04-28
ZA200401302B (en) 2005-01-04
MXPA04003365A (es) 2004-07-23
US20080027032A1 (en) 2008-01-31
RU2004114560A (ru) 2005-05-20
NO20041432D0 (no) 2004-04-05
KR20040044891A (ko) 2004-05-31

Similar Documents

Publication Publication Date Title
BR0213181A (pt) Combinações de inibidor de cox-2
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DE69827821D1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
BR0113669A (pt) Inibidores da desacetilase
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ES2178298T3 (es) Compuestos anti-inflamatorios.
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
BR9805544A (pt) Uso de um composto.
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
CL2003002356A1 (es) Compuestos derivados de 1-(1-acetil-piperidin-4-il)-(ester o amida)-4-(bencidrilo sustituido)-2-tert-butil-piperazina, composicion farmaceutica, y su uso en la inhibicion de 17b-hidroxiesteroide deshidrogenasa de tipo 3 y de enfermedades que dependen
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida
PT1292290E (pt) Composicoes farmaceuticas que compreendem derivados de acriloil-distamicina e inibidores de topoisomerase 1 e ii
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
BR9908885A (pt) Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/60, A61P 29/00

Ipc: A61K 31/60 (2011.01), A61P 29/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.